Remotely Delivered Mindfulness-Based Diabetes Education
- Disease/Condition
- Type 2 Diabetes
- Drug/Device/Intervention
- Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- University of Alabama at Birmingham
- Phase
- N/A
- Start date
- Jul 01, 2024
- End date
- Jun 30, 2026
- Enrollment
- 80 participants
Feasibility: percentage of screened participants who are eligible,Feasibility: percentage of eligible participants who enroll,Feasibility: ability to randomize participants to study arms,Feasibility: distribution of participants by demographics,Feasibility: percentage of sessions attended,Feasibility: participant adherence to study tasks include home mindfulness practices, self-monitoring activities.,Feasibility: barriers to participation in intervention sessions or completing study activities at home,Feasibility: reasons for dropping out,Feasibility: overall study retention,Acceptability
Diabetes distress is common affecting over one-third of people with type 2 diabetes,
 negatively impacting self-management and outcomes, and disproportionately affecting
 low-income individuals. The proposed project will conduct a pilot randomized controlled trial
 comparing remotely delivered Mindfulness-Based Diabetes Education plus remote patient
 monitoring of blood glucose to standard Diabetes Self-Management Education in rural Black
 adults with type 2 diabetes and elevated diabetes distress who receive care within federally
 qualified health centers to assess feasibility and acceptability.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06312553
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06312553 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.